Lumexa Imaging Holdings, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Lumexa Imaging reported Q2 2026 consolidated revenue of $264.2M (+5.1% YoY) with net income of $2.7M versus $7.2M loss prior year. The company announced a new joint venture with Hospital for Special Surgery (HSS), its ninth health system partnership, and four new imaging centers YTD. Full-year 2026 guidance narrowed Adjusted EBITDA range to $235M–$241M (prior: $234M–$242M), reiterating revenue guidance of $1.045B–$1.097B and Adjusted EPS of $0.71–$0.77. Adjusted EBITDA margin compressed 100 bps to 21.4% in Q2; same-center advanced volume growth 5.2% consolidated, 4.9% system-wide.
Why this rating
Modest mid-single-digit revenue growth with margin compression and unchanged FY guidance midpoint. HSS deal strategically notable but immaterial to ~$1.8B asset base. Routine quarterly disclosure for a now-public company.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.